lundi 22 août 2016

Onco Actu du 22 août 2016

1. Biologie

New study shows breast tumors evolve in response to hormone therapy [Washington University in St. Louis]

2. Etiologie

Vaginal douching 'linked to increased ovarian cancer risk' [NHS Choices]

2.11 Etiologie - Alimentation

From eggs to bacon – why food scares don’t scare us [The Guardian]

2.4 Etiologie - Portables, ondes e-m

How to think about the risks of mobile phones and Wi-Fi [The Guardian]

2.5 Etiologie - Gènes

Genes linked to rare cancer affecting children and young adults uncovered [The Guardian]

2.6 Etiologie - Environnement

Air pollution tied to shorter survival with lung cancer [Reuters]

3. Prévention

Public Health: We’re So Confused: The Problems With Food and Exercise Studies [NY Times]

3.1 Tabac

Protecting the Public and Especially Kids from the Dangers of Tobacco Products, Including E-Cigarettes, Cigars and Hookah Tobacco [FDA Voice]

3.1.1 Tabac - e-cigs

Low cost, flavors, convenience turn teens on to vaping: study [Reuters]

4. Dépistage, diagnostic et pronostic

Gene Expression Profile May Identify Patients with Renal Cell Carcinoma Unlikely to Benefit From Nivolumab [AACR]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

FoundationOne® Accepted by FDA and CMS for Parallel Review and FDA Expedited Access Pathway [Foundation Medicine]

4.2 Dép., diag. & prono. - Génome

Why Gene Tests for Cancer Don't Offer More Answers [Scientific American]

5. Traitements

Two New Drugs Show Promise for Patients with Aggressive Breast Cancer [Penn Medicine]

In cancer, it’s back to the future as old treatments make cutting-edge ones more effective [STAT]

5.10 Traitements - Essais

Lilly breast cancer drug stumbles, but trial continues [Reuters]

Momenta halts PhII pancreatic cancer trial after interim futility analysis [FierceBiotech]

Elizabeth Warren demands open access to data from patient trials of drugs [STAT]

Many pediatric clinical trials go unpublished or unfinished [STAT]

5.12 Immunothérapies

Why Does Immunotherapy Not Benefit Everyone Long-term? [CANCER RESEARCH Catalyst]

A Painful Cancer Advertisement [In the Pipeline]

Immune analysis of on-treatment longitudinal biopsies predicts response to melanoma immunotherapy [MD Anderson]

Immune System and Spirit Kept Cancer at Bay for a Year [NY Times]

Chance Collaboration Yields an Advance in Cancer Treatment [Wall Street Journal]

5.12.1 Immunothérapies - partenariats

Amgen, Regeneron Forge New, Separate Cancer Immunotherapy Pacts [The Street]

5.12.2 Immunothérapies - CAR-T

Juno Therapeutics Announces Multiple Myeloma Partnership with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics for Developing CAR T Cell Immunotherapy Against Multiple Novel Targets [Juno Therapeutics]

5.12.4 Immunothérapies - Essais

A key trial for a Bristol-Myers cancer drug fails in a ‘major surprise’ [STAT]

Merck Surges As Bristol’s Immunotherapy Drug Stumbles in Lung Cancer [Xconomy]

Bristol-Myers Executives: We Took A Bold Risk With Failed Lung Cancer Study [Forbes]

Bristol-Myers Squibb's Defeat Is A Victory For Personalized Medicine [Forbes]

Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer [BMS]

Bristol-Myers Shares Sink as Lung-Cancer Drug Misses Goal [Wall Street Journal]

Lung Cancer Drug Opdivo Fails Clinical Trial to Expand Use [NY Times]

5.2 Pharma

PharmaMar pits small cell lung cancer hopeful against competition in PhIII trial [FierceBiotech]

Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer [Novartis]

5.2.2 Pharma - Fusions & Acquisitions

Pfizer Confirms $14B Takeover of Cancer Drugmaker Medivation [The Street]

Pfizer Said Close to $14 Billion Deal to Acquire Medivation [Bloomberg]

5.3 Traitements - FDA, EMA,...

Adaptive pathways: key learnings and next steps [EMA]

5.3.4 Traitements - AMM (FDA, EMA)

FDA approves Heron's therapy for chemotherapy-induced nausea [Reuters]

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy [Merck]

5.4 Traitements - Economie

ICER Addresses Misconceptions about its Goals and Methods of Value Assessment [ICER]

Drug companies offer 'money back guarantees' to make cutting-edge therapies more attractive [The Telegraph]

Cancer drug companies cut prices to win NHS approval [The Guardian]

NHS cancer patients missing out on innovative drugs [The Guardian]

6.5 Médecines alternatives

3-Bromopyruvate: The latest cancer cure “they” don’t want you to know about [Science-Based Medicine]

Candidate cancer drug suspected after death of three patients at an alternative medicine clinic [Science]

Combatting the alt-med stereotype of oncologists anxious to administer toxic chemotherapy [Respectful Insolence]

6.7 DMP, Big Data & applis

Protecting privacy in genomic databases [MIT News]

As U.S. Looks to Launch Precision Health Study, Google's Role Emerges [Xconomy]

How can we encourage cancer patients to share their health data? [STAT]

6.7.1 Bioinformatique

Why Doctors Want A Computerized Assistant For Cancer Care [NPR]

21 Hospitals Across China to Adopt Watson for Oncology to Help Physicians Personalize Cancer Care [PR Newswire]

6.8 Communication

Andrew McDonald: The war of words about cancer [BMJ Blogs]

6.9 Controverses

Imprecise research threatens precision medicine [STAT]

NEJM editorial doubles down on resistance to data sharing [STAT]